

FOI Release

Information released under the Freedom of Information Act

Title: Office for Life Sciences spend on work to support the Accelerated Access Review

Date of release: 3 May 2016

Information request

1. How much did the Office of Life Sciences spend on externally provided work to support the Accelerated Access Review in the 2014/15 and 2015/16 financial years?
2. How much did the following work and related reports cost:
 - The Evidence Centre, Accelerated Access Review Themes in feedback following the Interim Report, Mar 2016
 - RAND Europe, Galvanising the NHS to adopt innovation, Feb 2016 and RAND Europe, The feasibility and practicality of recommendations from the interim report of the Accelerated Access Review, Appendix A, Feb 2016
 - Strategy& PWC, Accelerated Access Review: Proposition 2 Getting ahead of the curve Recommendations for accelerated access pathways and a flexible pricing and reimbursement framework, Mar 2016
 - Strategy&PWC, The Early Access to Medicines Scheme (EAMS): An independent review, Mar 2016
 - CASMI, Medicines Adaptive Pathways for Patients (MAPPS), Feb 2016
 - Monitor Deloitte (and CASMI, The Kings Fund), Accelerated Access Review: UK mapping, Mar 2015
 - RAND Europe (and the Policy Institute at King's, PRISM), Insights on earlier adoption of medical innovations: An international review of emerging and effective practice in improving access to medicines and medical technologies, 2015
 - Accelerated Access Review: Key themes from survey responses, Oct 2015
 - The Evidence Centre, Accelerated Access Review: Key themes in responses to engagement exercise, Oct 2015
 - Strategy& PWC, International pricing and reimbursement schemes Case studies report, Oct 2015
 - Survey on the attractiveness of different pricing and reimbursement schemes for the UK

Information released

To note: Office for Life Sciences sits jointly across Department of Health and Department for Business Innovation and Skills and in this instance, all costs listed were spent by Department of Health.

1. How much did the Office of Life Sciences spend on externally provided work to support the Accelerated Access Review in the 2014/2015 and 2015/2016 financial years?

In 2014/2015, £119,000 was spent on externally provided work to support the Accelerated Access Review and £420,035 in 2015/2016.

2. How much did the following work and related reports cost?

The Evidence Centre, Accelerated Access Review Themes in feedback following the Interim Report, Mar 2016

The Evidence Centre, Accelerated Access Review: Key themes in responses to engagement exercise, Oct 2015

The combined cost of the Evidence Centre reports was £30,000.

RAND Europe, Galvanising the NHS to adopt innovation, February 2016 and RAND Europe, The feasibility and practicality of recommendations from the interim report of the Accelerated Access Review, Appendix A, Feb 2016

The reports were funded by Wellcome Trust and cost £49,654.32 incl. VAT.

Strategy & PWC, Accelerated Access Review, Proposition 2 Getting ahead of the curve, Recommendations for accelerated access pathways and a flexible pricing and reimbursement framework, Mar 2016

Strategy & PWC, The Early Access to Medicines Scheme (EAMS): An independent review, Mar 2016

Strategy & PWC, International pricing and reimbursement schemes Case studies report, Oct 2015

Survey on the attractiveness of different pricing and reimbursement schemes for the UK

These reports were joint funded by Office for Life Science (OLS) and the Wellcome Trust. OLS contribution was £77,500 and the Wellcome Trust contribution was £155,000 including VAT and expenses.

CASMI, Medicines Adaptive Pathways for Patients (MAPPS), Feb 2016

The CASMI work was not commissioned specifically or funded by the OLS as part of the Accelerated Access Review (AAR). It was originally authorised and funded as part of wider Departmental Health work, prior to the initiation of the AAR.

It was realised that this work had relevance to the AAR and a small final component regarding real world data was defined as a specific AAR-directed piece of work.

The CASMI work cost £125,000 in total.

Monitor Deloitte (and CASMI, The Kings Fund) Accelerated Access Review: UK mapping, Mar 2015

This report cost £119,000.

RAND Europe (and the Policy Institute at King's PRISM), Insights on Earlier Adoption of medical innovations: An international review of emerging and effective practice in improving access to medicines and medical technologies, 2015

RAND Europe was not funded directly by OLS. It was funded by the Research and Development Directorate as part of their contribution to the Review and cost £72,000.

Accelerated Access Review: Key themes from survey responses, Oct 2015

This report was internally developed by the AAR team at no external cost.